A PHASE II RANDOMIZED CONTROLLED TRIAL OF NIVOLUMAB IN COMBINATION WITH BMS-986253 OR CABIRALIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS
Brief description of study
The purpose of this research study is to determine whether treatment with Cabiralizumab or HuMax-IL8 in combination with Nivolumab has additional benefit to Nivolumab treatment alone for treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.
Clinical Study Identifier: s18-01028
ClinicalTrials.gov Identifier: NCT04050462
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
